← Leaderboards
Dennis Brown
Kintara Therapeutics, Inc.
$1,999,439
Attributed
$1,999,439
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2023–24$2M$1.5M$1M$500K$0
'23
'24
Funding mix
By agency
NIH$1,999,439 · 1
By mechanism
R44$1,999,439 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Acute”
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Christopher J. Lindsell · Vanderbilt University Medical Center$8,536,327
- Michael E. Roth · Public Health Institute$8,201,777
- Jacob Sutton Coverstone · Neurovations$6,882,205
- Agustin G Yip · Albert Einstein College Of Medicine$6,090,308
Research focus
AcuteAdverse EventAftercareAreaAssociated SymptomCalibrationClinical ResearchCohort StudiesCommon Terminology Criteria For Adverse EventsCoupledCustomCutaneousDermalDesignDigital PhotographyDimensionsDosageDoseEfficacy EvaluationEfficacy StudyElectrocardiogramEligibility DeterminationEvent3-Dimensional
Grant awards (2)
An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)$745,259
R44 · FY2024 · CA · contact PI
An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)$1,254,180
R44 · FY2023 · CA · contact PI